Taffy Makaya, Rebecca Poole and Kavitha Rozario
122
[75] Wilding J, Van Gaal L, Rissanen A Vercruysse F, Fitchet M; OBES- 002
Study Group. 2004. ‘A randomized double-blind placebo-controlled
study of the long-term efficacy and safety of topiramate in the treatment
of obese subjects’. Int J Obes Relat Metab Disord. 28:1399-410.
[76] Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A,
Fitchet M. 2005. ‘Efficacy and safety of topiramate in the treatment of
obese subjects with essential hypertension’. Am J Cardiol. 96:243-251.
[77] Tremblay A, Chaput JP, Berube-Parent S, Prud'homme D, Leblanc C,
Alméras N, Després JP. 2007. ‘The effect of topiramate on energy
balance in obese men: a 6-month double-blind randomized placebo-
controlled study with 6-month open-label extension’. Eur J Clin
Pharmacol. 63(2):123-34.
[78] Li HF, Zou Y, Xia ZZ, Gao F, Feng JH, Yang C. 2009. ‘Effects of
topiramate on weight and metabolism in children with epilepsy’. Acta
Paediatr. 98(9):1521-5.
[79] Colman, E. 2012. ‘Food and Drug Administration’s Obesity Drug
Guidance A Short History’. Circulation. 125(17):2156-64.
[80] Cosentino G, Conrad AO, Uwaifo GI. 2011. ‘Phentermine and
topiramate for the management of obesity: a review’. Drug Des Devel
Ther. 7:267-78.
[81] Yanovski, S et al. Long-term Drug Treatment for Obesity, a systematic
and clinical review JAMA 2014, 311 74-86.
[82] Haddock CK, Poston WS, Dill PL et al. Pharmacotherapy for obesity: a
quantitative analysis of four decades of published randomized clinical
trials. Int J Obes Relat Metab Disord.2002;26(2):262–273.
[83] Runyan JW Jr. 1962. ‘Observations on the use of phendimetrazine, a
new anorexigenic agent, in obese diabetics’. Curr Ther Res Clin
Exp.;4:270-275.
[84] Hadler AJ. 1968. ‘Sustained-action phendimetrazine in obesity’. J Clin
Pharmacol J New Drugs. 8(2):113-117.
[85] Taylor JR, Dietrich E, Powell J. 2013. ‘Lorascerin for weight
management’. Diabetes Metab Syndr Obes. 6:209-16.
[86] Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe
S, Bays H, Shanahan WR; Behavioral Modification and Lorcaserin for
Overweight and Obesity Management (BLOOM) Study Group. 2010.
‘Multicenter, placebo-controlled trial of lorcaserin for weight
management’. Engl J Med. 363:245-256.